Bristol Myers Squibb Presents New Long-Term and Real-World Data on Camzyos for Obstructive Hypertrophic Cardiomyopathy
Reuters
Nov 03
Bristol Myers Squibb Presents New Long-Term and Real-World Data on Camzyos for Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb has announced new data from its cardiovascular portfolio to be presented at the American Heart Association's Scientific Sessions 2025, scheduled for November 7-10 in New Orleans, Louisiana. The presentations will include results from a long-term extension study and real-world evidence on Camzyos (mavacamten), which is used in the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data are expected to reinforce Camzyos' effectiveness in reducing obstruction and improving symptoms in oHCM patients. Additionally, research from the Bristol Myers Squibb-Johnson & Johnson Collaboration will be presented, including a study on milvexian and outcomes associated with direct oral anticoagulant dosing in patients with atrial fibrillation. The results are scheduled to be presented at the upcoming conference and have not yet been disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103978786) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.